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Abstract
A novel polymorphism in the extracellular domain 2 (EC2)
of FcgRIIIA affects ligand binding by natural killer (NK)
cells and monocytes from genotyped homozygous normal
donors independently of receptor expression. The nonconservative T to G substitution at nucleotide 559 predicts a
change of phenylalanine (F) to valine (V) at amino acid position 176. Compared with F/F homozygotes, FcgRIIIa expressed on NK cells and monocytes in V/V homozygotes
bound more IgG1 and IgG3 despite identical levels of receptor expression. In response to a standard aggregated human
IgG stimulus, FcgRIIIa engagement on NK cells from V/V
(high-binding) homozygotes led to a larger rise in [Ca21]i, a
greater level of NK cell activation, and a more rapid induction of activation-induced cell death (by apoptosis). Investigation of an independently phenotyped normal cohort revealed that all donors with a low binding phenotype are F/F
homozygotes, while all phenotypic high binding donors have
at least one V allele. Initial analysis of 200 patients with SLE
indicates a strong association of the low binding phenotype
with disease, especially in patients with nephritis who have
an underrepresentation of the homozygous high binding
phenotype. Thus, the FcgRIIIa polymorphism at residue
176 appears to impact directly on human biology, an effect
which may extend beyond autoimmune disease characterized by immune complexes to host defense mechanisms. (J.
Clin. Invest. 1997. 100:1059–1070.) Key words: receptors, Fc •
polymorphism, genetics • macrophages • killer cells, natural • lupus erythematosus, systemic

Introduction
Genetic polymorphisms of human FcgRIIa and FcgRIIIb have
been characterized (1–13) and associated with certain disease
risks (14–20). The two allelic forms of FcgRIIa differ by two
nucleotides (nt),1 one in the first extracellular Ig-like domain
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(EC1) predicting a glutamine (Q) to tryptophan (W) at residue
position 27 and one in the second extracellular Ig-like domain
(EC2) predicting an arginine (R) to histidine (H) at residue
position 131. The change at position 131 markedly alters the
ability of the receptor to bind human IgG2 (10, 12), and this
polymorphism has been associated with certain bacterial infections (14, 15, 19) and with SLE (16–18). The two allelic forms of
neutrophil-specific FcgRIIIb differ by five nucleotides which
results in four amino acid differences in EC1 (21). Although
binding of IgG does not seem to be affected (9), these two allelic forms do have different levels of quantitative function (9,
10), and the more active NA1 allele has been associated with
severe renal disease in certain systemic vasculitides (20).
Several recent observations suggest that FcgRIIIa, which is
expressed on natural killer (NK) cells, mononuclear phagocytes, and renal mesangial cells (22), might also be polymorphic in both its structure and quantitative expression. Vance
and Guyre originally described a functional polymorphism in
FcgRIIIa on NK cells among normal donors (23). Based on
some differences both in IgG binding and in anti-CD16 reactivity, they suggested that variations in receptor expression
might explain their observations. More recently, de Haas and
colleagues have described a triallelic sequence polymorphism
at nt 230 in FcgRIIIA (24). This single nucleotide substitution
in the third exon encoding EC1 predicts an amino acid change
from leucine (L) to arginine (R) or from leucine (L) to histidine (H) and reportedly influences the binding of human IgG
and several anti-CD16 mAbs (24, 25). Such structural variants
of FcgRIIIa, recognized by altered patterns of anti-CD16 mAb
binding, may be related to a clinical phenotype of repeated infections (26).
The FcgRIIIA sequence polymorphism on NK cells which
reportedly influences ligand binding (24) raised the possibility
that this sequence polymorphism might explain previously described differences in NK FcgRIIIa and NK cell function (23,
26). To test this hypothesis, we identified several of the normal
donors studied by Vance and Guyre (23) and characterized the
nucleotide sequence of their FcgRIIIA. Contrary to our expectation, these donors were monomorphic at nt 230 and nt
248 (amino acid positions 66 and 72).2 However, they were
polymorphic at nt 559, a site noted by Ravetch and Perussia as

1. Abbreviations used in this paper: ADCC, antibody-dependent cellular cytotoxicity; EC, extracellular domain; GAM, goat anti–mouse
IgG; MNC, mononuclear cells; NK, natural killer; nt, nucleotide; PE,
phycoerythrin; PI, propidium iodide; TC, tri-color.
2. The first amino acid of the signal sequence is designated amino acid
1 (21). In this nomenclature, nt 559, 230, and 248 are in the codons for
amino acids 176, 66, and 72, respectively. Using the first amino acid of
EC1, others have designated nt 230 and 248 polymorphisms as amino
acids 48 and 64.
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potentially polymorphic (21). This nonconservative T to G
substitution predicts a change of phenylalanine (F) into valine
(V) at position 176 in the membrane-proximal EC2. Since several studies suggest that the second Ig-like domain strongly influences ligand binding (27–32), we pursued further characterization of this 176F/V polymorphism by identifying normal
donors homozygous at position 176 (and homozygous at positions 66 and 72). Compared with F/F homozygotes, FcgRIIIa
expressed in V/V homozygotes bound more IgG1 and IgG3
despite identical levels of receptor expression. These observations indicate that the sequence polymorphism at nt position
559 alters the apparent affinity of FcgRIIIa on both NK cells
and monocytes for IgG. This difference affects the ability of
the receptor to initiate a range of cell programs in response to
a standard stimulus and underlies the previously described
variation in NK FcgRIIIa function (23). Initial analysis of 200
patients with SLE indicates a strong association of the low
binding phenotype with disease, especially nephritis, and a corresponding underrepresentation of the homozygous high binding phenotype. Thus, this polymorphism appears to impact directly on human biology, an effect which may well extend
beyond autoimmune disease characterized by circulating immune complexes.

Methods
Donors. Anticoagulated peripheral blood was obtained from healthy
normal volunteers and from 200 patients fulfilling the revised criteria
of the American College of Rheumatology for SLE (33). All studies
were reviewed and approved by each Institutional Review Board and
all donors provided written informed consent.
Reagents. Human IgG (hIgG) subclass proteins were obtained
from The Binding Site (San Diego, CA) or Sigma Chemical Co. (St.
Louis, MO). All mAbs used were murine origin. Anti–human CD56phycoerythrin (PE), anti–human CD14-tri-color (TC), anti–human
CD3-FITC, anti-CD25-FITC, and anti-CD33-FITC were from Caltag
Laboratories (Burlingame, CA). Anti-FcgRI (mAb 197, mIgG2a and
mAb 22.2, mIgG1), anti-FcgRII (mAb IV.3, mIgG2b), and antiFcgRIII (mAb 3G8-FITC, mIgG1) were from Medarex Inc. (Annandale, NJ). Other anti-FcgRIII mAbs used in this study were CLBFc
Rgran1 (mIgG2a), B73.1 (mIgG1), 1D3 (mIgM), MEM154 (mIgG1),
30.2 (mIgG1), 214.1 (mIgG1), 135.9 (mIgG1), GRM1 (mIgG2a), and
Leu11a (mIgG1). 1D3, MEM154, and CLBFcRgran1 were obtained
through the 5th Leukocyte Typing Workshop. mAbs 30.2, 214.1, and
135.9 were generously provided by Dr. Howard Fleit (SUNY, Stony
Brook, NY) (34); mAb GRM1 was from Research Diagnostics Inc.
(Flanders, NJ). B73.1 (Leu11a) and Leu11a-FITC were obtained from
Becton Dickinson Immunocytometry Systems (San Jose, CA). FITCconjugated and unconjugated goat anti–mouse IgG(H 1 L) (GAM),
which recognizes mIgG1, IgG2a, and mIgM, was obtained from Boehringer Mannheim (Indianapolis, IN) and Jackson ImmunoResearch
(West Grove, PA). Heat-aggregated human IgG was prepared by incubating the hIgG (Sigma), 20 mg/ml, at 638C for 20 min.
Mononuclear cell (MNC) and NK cell preparation. Fresh anticoagulated blood was diluted 1:1 in Hanks’ buffer (GIBCO BRL,
Gaithersburg, MD) and centrifuged through a discontinuous two-step
Ficoll-Hypaque gradient in 50-ml conical tubes (35). MNC were harvested from the upper and neutrophils from the lower Ficoll-Hypaque
interface and washed three times with PBS, pH 7.4. After the last
wash, the cells were resuspended, counted, and used either for
mRNA preparations, for quantitative flow cytometry, or for further
purification of NK cells.
NK cells were purified with the NK Cell Isolation Kit (Miltenyi
Biotec Inc., Auburn, CA) which depletes human T cells, B cells, and
myeloid cells from MNC by magnetic separation. Isolated NK cells
1060
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were washed with Ca21- and Mg21-free PBS, pH 7.4, and assayed for
purity by flow cytometry with either the combination of anti-CD3FITC, anti-CD14-TC, and anti-CD56-PE or the combination of 3G8FITC, anti-CD14-TC, and anti-CD56-PE. Starting with 5 3 107 MNC,
the yield of NK was typically 4–5 3 106 total cells with a purity of
. 85%. The efficiency of NK cell recovery was z 75%.
Nucleic acid isolation. Total RNA was isolated from 107 MNC by
using TRIzol™ total RNA isolation reagent (GIBCO BRL). 5 mg of
total MNC RNA was used to synthesize cDNA with the SuperScript™
preamplification system (GIBCO BRL). For sequencing of genomic
DNA and for allele-specific PCR, genomic DNA was isolated using
the Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN).
RT-PCR and cDNA sequencing. To facilitate heterozygote detection, a dye primer strategy was used for fluorescence-based automated cycle sequencing of PCR product on an ABI 377 (ABI PRISM™
Dye Primer Cycle Sequencing -21M13 FS and M13REV FS Ready
Reaction Kits; Applied Biosystems, Inc., Foster City, CA). Two overlapping sets of primers, with either M13 universal or reverse primer
sequences at the appropriate 59 ends, were designed for the FcgRIIIA
cDNA. Sequencing set 4 (Fig. 1) was used to amplify position 50 to
position 414: forward 59-CAG GAA ACA GCT ATG ACC TCC
CAA CTG CTC TGC TAC TT-39 and reverse 59-TGT AAA ACG
ACG GCC AGT CCT CAG GTG AAT AGG GTC TTC-39. Sequencing set 3 (Fig. 1) was used to amplify position 328 to position
869: forward 59-TGT AAA ACG ACG GCC AGT CCG GTG CAG
CTA GAA GTC CA-39 and reverse 59-CAG GAA ACA GCT ATG
ACC GGG GTT GCA AAT CCA GAG AA-39. The PCR products
were purified with the QIAquick Gel Extraction Kit (QIAGEN Inc.,
Chatsworth, CA).
Allele-specific PCR. Three primers were designed for allele-specific PCR for genotyping genomic DNA at position 559 in FcgRIIIA
(PCR set 1, Fig. 1 A). The FcgRIIIA-specific forward primer (59TCA CAT ATT TAC AGA ATG GCA ATG G-39) corresponds to
the FcgRIIIA sequence between position 449 and position 473 and
was used in both T allele–specific and G allele–specific PCR assays.
The reverse primers, corresponding to nt 586–559, provided allele
specificity. The nt 559 G-specific reverse primer (59-TCT CTG AAG
ACA CAT TTC TAC TCC CTA C-39) differs in one nucleotide from
T-specific reverse primer (59-TCT CTG AAG ACA CAT TTC TAC
TCC CTA A-39) at the 39 end. The allele-specific PCR product of 138 bp
was assayed on a 3% agarose gel. The PCR reaction was performed
in a GeneAmp 2400 PCR System with 360 ng of DNA, 200 nM of
each primer, 200 mM of dNTPs, 1.5 mM of MgCl, and 2.5 U of Taq
polymerase (Boehringer-Mannheim Biochemicals) in a 50-ml reaction
volume starting with 958C for 5 min, 35 cycles of denaturing at 948C
for 30 s, annealing at 518C for 45 s, and extension at 728C for 20 s with
a final extension at 728C for 7 min. The appearance of the 138-bp
PCR products in the T or G allele–specific reaction indicates the
presence of that allele.
Genomic DNA sequencing. To confirm FcgRIIIA genomic sequence, primers were designed to amplify a portion of exon 4 of
FcgRIIIA which corresponds to EC2 (sequencing set 1, Fig. 1 A).
The forward primer (59-TGT AAA ACG ACG GCC AGT TCA
TCA TAA TTC TGT CTT CT-39, corresponding to nt 486–505) includes an intentional mismatch six nucleotides from the 39 end to provide FcgRIIIA-specific priming. The reverse primer (59-CAG GAA
ACA GCT ATG ACC CTT GAG TGA TGG TGA TGT TCA-39)
corresponds to nt 610–590. The 162-bp PCR product containing the
nt 559 polymorphic site was purified from a 3% agarose gel with the
QIAquick Gel Extraction Kit. Fluorescence-based automated cycle
sequencing of PCR product was performed on an ABI 377 (ABI
PRISM™ Dye Primer Cycle Sequencing -21M13 FS and M13REV FS
Ready Reaction Kits).
To determine the FcgRIIIA genomic sequence of EC1, primers
were designed to amplify a portion of exon 3 encompassing nt positions 230 and 248 (sequencing set 2, Fig. 1 A). The forward primer
(59-CAG GAA ACA GCT ATG ACC CTC TTT CTG TAG CTT
GGT TC-39) anneals to the intron region between S1 and S2 of the

Figure 1. Schematic representation of the
FcgRIIIA genomic structure and cDNA
structure showing the relative location of
primers used for PCR-based sequencing
(sequencing sets 1–4) and allele-specific
PCR (PCR set 1). For sequencing analysis,
an M13-based dye-primer sequencing
strategy was used. FcgRIIIa encoding
cDNA was prepared from purified MNC.
Relative positions of nt 230 and 559 are
shown. S, Signal sequence (encoded in two
exons); TM/CY, transmembrane/cytoplasmic domains; 39-UT, 39 untranslated sequence.

FcgRIIIA gene. The reverse primer (59-TGT AAA ACG ACG GCC
AGT ATG GAC TTC TAG CTG CAC-39) corresponds to nt 348 to
331 in exon 3. The PCR product was purified and sequenced as described above.
Flow cytometric assay for human IgG binding. Human IgG binding assays were performed using anticoagulated, washed whole blood.
Mouse mAbs were used either for direct immunofluorescence (Leu11aFITC, 3G8-FITC) or for indirect immunofluorescence (3G8, Gran1,
B73.1, 1D3, MEM154, 30.2, 214.1, 135.9, GRM1) in conjunction with
FITC-labeled F(ab9)2 GAM. Human IgG subclass myeloma proteins
(IgG1, IgG2, IgG3, and IgG4) were directly conjugated with FITC according to standard techniques (36). Aggregates were removed by ultracentrifugation and removal was confirmed by the lack of binding
of the FITC-labeled myelomas to human neutrophils. Before each experiment, the flow cytometer (FACScan®; Becton-Dickinson Immunocytometry) was calibrated with quantitative fluorescein microbeads
(Flow Cytometry Standards Corp., Research Triangle Park, NC). Identification of individual cell populations was based on forward and
right angle light scattering in combination with three-color immunofluorescence using TC, PE, and FITC.
For each IgG binding assay, 3 ml of heparinized whole blood was
washed and cytophilic IgG was removed by incubation in 45 ml of
PBS at 378C for 20 min. For direct immunofluorescence, 100-ml aliquots of the washed whole blood were incubated at 48C for 1 h with
an hIgG-FITC myeloma protein (final concentrations of 15 and 30
mg/ml) or with anti-CD16 mAb [either directly FITC-conjugated or
indirectly with F(ab9)2 GAM IgG-FITC, see below] and with CD14TC and CD56-PE at 5 mg/ml. NK cells were identified as CD56-PE
positive, CD14-TC negative cells within the lymphocyte light scatter
gate; the binding of the different human IgG subclasses or the different anti-CD16 mAbs was assessed by the intensity of FITC fluorescence. Blood monocytes were identified as CD14-TC positive, CD56negative cells within the typical blood monocyte light scatter gate. For
myeloma protein binding to monocyte FcgRIIIa, washed whole blood
was preincubated at 48C for 10 min with mAb 197 IgG (10 mg/ml) to
block the ligand binding site of FcgRI (12).
For the anti-CD16 mAb panel assay, washed whole blood cells
were incubated with a saturating concentration of primary mAb for
30 min, washed twice with PBS, incubated with FITC-conjugated goat
F(ab9)2 anti–mouse IgG at 48C for 30 min, and washed twice with
PBS. After blocking remaining GAM binding sites with control
mIgG1 and mIgG2a (10 mg/ml final concentration), CD14-TC and

CD56-PE were added for phenotypic identification. After further incubation and washes, cells were analyzed on the FACScan®.
Measurement of change in [Ca21]i. Changes in intracellular [Ca21]i,
induced by cross-linking of purified NK cell FcgRIIIa with heataggregated human IgG or with anti-FcgRIIIa mAb, were determined
in purified indo-1-AM–loaded NK cells using an SLM 8000 spectrofluorometer and the simultaneous 405/490 nm fluorescence emission ratio as described previously (37, 38). Briefly, cells in suspension
at 107 cells/ml in Ca21- and Mg21-free PBS, pH 7.4, were incubated
with 5 mM indo-1-AM at 378C for 15 min and washed in PBS. Cell
preparations to be opsonized with mAb 3G8 were resuspended in
Ca21- and Mg21-free PBS at 107 cells/ml, incubated with saturating
concentrations of 3G8 (10 mg/ml) at 378C for 5 min, and washed in
PBS. All cells were resuspended in 1.1 mM Ca21, 1.6 mM Mg21 PBS
at 378C for 5 min and then immediately transferred to a continuously
stirring cell cuvette maintained at 378C in the SLM 8000. With excitation at 355 nm, the simultaneous fluorescence emission at 405 and 490
nm was measured, integrated, and recorded each second. After establishing a base line for 60 s, either aggregated human IgG or goat
F(ab9)2 anti–mouse IgG was added at final concentrations of 20 or 35
mg/ml, respectively, and data acquisition was continued for an additional 3.5 min. Each sample was individually calibrated by lysing cells
in 1% Triton X-100 to determine the maximal emission ratio and by
adding EDTA (20 mM final concentration) to determine the minimal
ratio. The indo-1 fluorescence emission ratio was converted to [Ca21]i
by the method of Grynkiewicz (39).
Induction of NK cell IL-2 receptor (CD25) expression and cell viability. Purified NK cells were cultured in RPMI/10% FCS and rIL-2
(100 U/ml) with or without a defined stimulus for varying periods of
time in 96-well plates. FcgRIIIa-mediated stimulation of NK cells was
effected either with the anti-FcgRIIIa mAb 3G8 IgG (10 mg/ml) or
with heat-aggregated human IgG (20 mg/ml). For mAb stimulation,
wells were precoated with 10 mg/ml F(ab9)2 GAM (Jackson ImmunoResearch) for 2 h at 378C, rinsed, and 105 NK cells (106 cells/ml)
were added with mAb and incubated for various periods of time. Aggregated human IgG was used either in solution as a soluble stimulus
or immobilized to the tissue culture plated (precoating for 2 h at
378C) before the addition of cells. Since induction of CD25 expression was observed within 1 h of stimulation as previously reported
(40, 41), we examined incubation periods ranging from 1 to 48 h.
CD25 expression was determined by flow cytometry using anti-CD25FITC (Caltag Laboratories).
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The viability of purified and 24-h IL-2–primed (100 U/ml) NK cells
after FcgRIIIa-mediated stimulation was determined by quantitation
of propidium iodide (PI) uptake in the FACScan® and by direct visual assessment of trypan blue exclusion. Significant changes in cell
viability could be detected within 1 h of stimulation with mAb or aggregated IgG (42–44). To determine if FcgRIIIa-mediated stimulation was inducing cell death via apoptosis, in selected experiments
cells were fixed, permeabilized, and analyzed for quantitative DNA
content. Subdiploid uptake of PI reflects cell death via apoptosis (45).

Additionally, we examined stimulated cells for apoptotic morphology
(chromatin condensation and nuclear fragmentation) (43) after fixation (2% paraformaldehyde plus 0.5% glutaraldehyde in 0.05 M cacodylate buffer, pH 7.2, followed by post-fixation with 1% osmic acid
in cacodylate buffer, pH 7.2). Cells were suspended in 1.5% agar, embedded in Spurr’s resin, and the thin sections were viewed in a Phillips CM-12 electron microscope.
Statistical analysis. Differences in ligand binding and mAb binding were analyzed by Student’s t test. The x2 test was used to analyze

Figure 2. Sequence analysis of a portion of
FcgRIIIa cDNA from three normal donors. FcgRIIIa encoding cDNA was prepared from purified MNC and an M13based dye-primer sequencing strategy was
used (see Methods). Donors homozygous
for nt 559-T (A), homozygous for nt 559-G
(C), and a donor heterozygous for nt
559-T/G (B) are shown. In each tracing, nt
531 (*) is shown to indicate the presence of
cDNA encoding the FcgRIIIA gene (C at
nt 531) and not the FcgRIIIB gene (which
is T at nt 531).
1062
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the distribution of FcgRIIIA genotypes (corresponding to 176-V/V,
176-F/F, and 176F/V) in SLE and non-SLE controls. The null hypothesis was rejected at the 95% confidence level (P , 0.05).

Results
FcgRIIIA sequence polymorphisms. The recent observation of
an FcgRIIIA sequence polymorphism on NK cells which influences ligand binding (24) raised the possibility that this sequence polymorphism might explain previously described differences in NK FcgRIIIa and NK cell function (23). To test
this hypothesis we identified several of these normal donors
and characterized the nucleotide sequence of their FcgRIIIA.
The cell type specific expression of FcgRIIIA and FcgRIIIB in
NK cells/mononuclear phagocytes and in neutrophils, respectively, provides a strategy for selective sequencing of cDNAs
derived from these two highly homologous genes. Furthermore, within the coding region of FcgRIII, there are 10 nucleotide differences between FcgRIIIA and FcgRIIIB that can be
used to confirm the presence of only FcgRIIIA or FcgRIIIB
sequence. Using this approach, two normal donors, one with
the low binding FcgRIIIa phenotype and one with a high binding FcgRIIIa phenotype (23), were both shown to be T/ T230
homozygotes. Interestingly, however, while the low FcgRIIIa
phenotype showed no differences from the conventional sequence, the donor characterized phenotypically as high binding
FcgRIIIa was heterozygous T/G at nt 559 (Fig. 2). This nucleotide difference, previously mentioned by Ravetch and Perussia (21), raised the possibility that this nonconservative nucleotide polymorphism encoding a phenylalanine to valine at
amino acid residue 1762 in the membrane proximal EC2 of
FcgRIIIa might affect ligand binding and receptor function.
Sequence analysis of the entire coding region for MNC

FcgRIIIA cDNA from a total of 30 normal donors revealed
variation in nt position 559 (T or G). In this group, cDNAs
from three individuals contained only G559 while six donors
contained only T559. The remaining 21 donors were found to
contain both T559 and G559 (Fig. 2). All 30 normal donors were
homozygous T at nt 230 and homozygous C at nt 248 (24, 25).
There were no other sequence differences throughout the
whole FcgRIIIA gene except that two donors were heterozygous at position 249 for a conservative G249 to A249 substitution, a silent variation at the third position of the codon for
serine. These data demonstrate that the sequence variation in
the FcgRIIIA gene at nt 559 (amino acid 176) is not a rare mutation, but rather a common polymorphism.
Characterization of CD16 epitopes. To determine if the 176F
to V change affects the binding of anti-CD16 mAb which
might explain previously reported variations in anti-CD16
mAb reactivity (28, 30, 31, 46, 47), the reactivity of FcgRIIIa
on peripheral blood NK cells was characterized using a panel
of anti-CD16 mAb. Donors homozygous for 176F or 176V and
homozygous for 66L2 and 72S2 were examined by flow cytometry. Using the well characterized anti-CD16 mAb CLB-Gran1,
identical CD16 fluorescence intensities were observed on
CD56 positive NK cells from donors of both genotypes (Fig. 3
A and Table I). Similar results were evident with six additional
anti-CD16 mAbs (Table I) including mAb B73.1 which is affected by the polymorphism at nt 230 (24, 25). mAbs 1D3 and
MEM154 showed differential binding to NK cells from donors
homozygous for F compared with V. In both instances, these
mAb bound well to 176V/V donors but only poorly to 176F/F
donors (Fig. 3, C and D, and Table I). mAb 3G8 showed subtle
differences which did not reach statistical significance with our
sample size (Fig. 3 B). These data indicate that although donors homozygous for either the F or the V alleles express the

Figure 3. CD16 mAbs MEM154 and 1D3
show differential reactivity with FcgRIIIa176V and FcgRIIIa-176F alleles. Lymphocytes and NK cells were identified in
washed whole blood by characteristic light
scatter properties and lack of reactivity
with anti-CD14. Anti-CD16 staining on the
CD142 lymphocytes is shown. Blood from
donors homozygous for FcgRIIIa-176V/V
and FcgRIIIa-176F/F was examined. Identical Gran1 reactivity (A) confirms identical receptor density between the two donors. As previously reported, mAb 3G8
binds slightly less to the FcgRIIIa-176F allele than the FcgRIIIa-176V allele (the
functional high binding phenotype, see Results) (B). mAbs 1D3 (C) and MEM154
(D) bound well to NK cells from the
FcgRIIIa-176V/V donor but reacted
poorly with NK cells from the FcgRIIIa176F/F donor. Data represent a single donor pair out of a total of five different donor pairs examined.
Novel Polymorphism of FcgRIIIa (CD16) and Autoimmune Disease
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Table I. CD16 Epitopes
Donor type
mAbs

mAb subclass

CLB-Gran1
GRM 1
B73.1
Leu11a
3G8
30.2
214.1
135.9
MEM154*
ID3‡

mIgG2a
mIgG2a
mIgG1
mIgG1
mIgG1
mIgG1
mIgG1
mIgG1
mIgG1
mIgM

FcgRIIIa-176V/V

FcgRIIIa-176F/F

n55

n55

1769696
12786108
1059615
337625
552669
803650
77617
945658
11696126
70615

16736191
1356664
11136138
395672
399676
698660
89614
802626
4866
34615

Reactivity of anti–human CD16 mouse mAbs with NK cells expressing
the different allelic forms of FcgRIIIa. Data shown are mean channel
fluorescence6SEM. ‡ P , 0.003, FcgRIIIa-176V/V vs. -176F/F; *P ,
0.001, FcgRIIIa-176V/V vs -176F/F.

same level of CD16 protein on the surface of NK cells, the reactivities for some anti-CD16 mAbs differ, suggesting that the
these allelic proteins have different three-dimensional structural characteristics.
We then examined the mAb epitopes expressed on CD16
positive circulating monocytes. This population, typically a small
percentage of circulating monocytes (35), was identified by
multicolor fluorescence. Because FcgRIIIa expression by monocytes is variable among donors, we sought donors homozygous
for 176F or 176V (and homozygous for both 66L and 72S) expressing comparable levels of mAb CLB-Gran1 reactivity on
their peripheral blood monocytes. In paired experiments, B73.1
showed identical reactivity while both 1D3 and MEM154
showed less reactivity with the 176 F/F donor (results not
shown).
Characterization of ligand binding. A single amino acid
change at residue 131 in the membrane proximal domain of
FcgRIIa (CD32) results in a nearly 10-fold alteration in quantitative ligand binding of human IgG2 (10–12). To determine if
the 176F/V polymorphism in the homologous extracellular domain of FcgRIIIa altered ligand binding, we examined the binding of pooled human IgG and of human IgG myeloma proteins
to peripheral blood leukocytes from our homozygous donors.
FcgRIIIa has a higher affinity for IgG than FcgRIIa and
FcgRIIIb. This higher affinity (reported to be in the range of
1–7 3 107 M21) is less than the affinity of IgG binding to FcgRIa,
but is sufficient to allow binding of monomer IgG at physiological concentrations. Binding of pooled human IgG to NK cells
was observed in all donors, but the level of binding was substantially different between our homozygous donor groups. Individuals homozygous for both 176V and 66L bound significantly more IgG1 and IgG3 than did donors homozygous for
both 176F and 66L (Fig. 4). The difference in binding of IgG1
and IgG3 was observed at both concentrations of IgG (15 and
30 mg/ml) used in these studies. Binding of the myeloma proteins to CD56 positive NK cells was completely blocked by the
anti-CD16 mAb CLB-Gran1 (results not shown). A difference
in binding of IgG4 (30 mg/ml) was also observed; there was de1064
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Figure 4. Binding of human IgG myeloma proteins to NK cell
FcgRIIIa on donors homozygous for 176V/V and 176F/F. NK cells in
washed whole blood were identified by characteristic light scatter
properties, by reactivity with anti-CD56, and by lack of reactivity
with anti-CD14. Binding of FITC-labeled human IgG1 (A) and IgG3
(B) (each at 30 mg/ml) to CD561/CD142 cells is shown. NK cells from
each donor expressed identical levels of CD16 (using mAb Gran1).
Data represent a single donor pair out of a total of five different donor pairs that were examined.

tectable but low binding to donors homozygous for 176V but
not 176F. mAb CLB-Gran1 was used to confirm identical levels of CD16 protein on the NK cell surface (Fig. 3). No binding
of IgG2 (30 and 15 mg/ml) or IgG4 (15 mg/ml) to NK cells from
either donor type was observed.
In a number of experiments, we were also able to observe
hIgG myeloma protein binding to FcgRIIIa on the small subset of human monocytes expressing CD16. Using preincubation with anti-CD64 mAb 197 to block the high affinity FcgRIa,
binding of human IgG to FcgRIIIa could be quantitated. Complete blockade of FcgRIa was confirmed by showing that the
binding of mIgG2a (30 mg/ml) was reduced to background autofluorescence levels in the presence of mAb 197 (Fig. 5 C). In
paired experiments with donor monocytes matched for CLBGran1 reactivity and with FcgRIa blocked by mAb 197, 176V
homozygous donors bound more hIgG1 than did donors homozygous for 176F (Fig. 5, A and B). These data document
that the nt 559 polymorphism of FcgRIIIA which changes a
single amino acid in EC2 results in a change in apparent affinity for ligand binding independent of the cell type in which it is
expressed.
Functional implications of the 176F/V polymorphism. To determine if the difference in quantitative binding of ligand to
the 176F and 176V alleles results in differences in receptor

Figure 5. Binding of human IgG1-FITC (30 mg/ml) to peripheral
blood monocyte FcgRIIIa on donors homozygous for 176V/V (A)
and 176F/F (B). Monocytes in washed whole blood were identified by
characteristic light scatter properties, by reactivity with anti-CD14
(bright and dim), and by lack of reactivity with anti-CD56. The ligand
binding site of the high affinity FcgRI was blocked by preincubation
with mAb 197. Complete blockade of ligand binding (mIgG2a) is
shown (C). Monocytes from each donor expressed identical levels of
CD16 (using mAb Gran1). Data represent a single donor pair out of
a total of four different donor pairs that were examined. Monocytes
from the fifth donor pair did not show significant reactivity with antiCD16. Background fluorescence levels are lower in C because of
lower detector settings used for the mAb binding panel.

function, we quantitated FcgRIIIa-induced NK cell activation.
Cross-linking of FcgRIIIa results in an immediate rise in [Ca21]i
(48, 49). When purified NK cells from 176F and 176V homozygous donors were stimulated with the anti-CD16 mAb 3G8

and F(ab9)2 GAM, a brisk rise in [Ca21]i was observed. The
magnitude of this rise in [Ca21]i in the homozygous donors was
indistinguishable (466 and 516 nM in the 176F and 176V homozygous donors, respectively; Fig. 6). When aggregated human IgG was used as the stimulus, a rapid rise in [Ca21]i was
also observed in the homozygous donors, but the magnitude of
the rise in NK cells from the 176V homozygote donor was
more than threefold greater than the rise observed in NK cells
from the 176F homozygote donor (56 and 189 nM in the 176F
and 176V homozygous donors, respectively; Fig. 6).
To examine the impact of the 176F/V polymorphism on integrated cell functions, upregulation of surface CD25 (IL-2 receptor) on IL-2–treated NK cells after engagement of FcgRIIIa
was assessed (40, 41). Stimulation with mAb 3G8 and F(ab9)2
GAM induced rapid upregulation of expression of CD25 (IL2R) on the surface of purified NK cells. Using purified NK
cells from homozygous donors, engagement and cross-linking
of CD16 with IgG aggregates also resulted in rapid upregulation of CD25 expression. However, donors homozygous for
176V showed significantly higher levels of CD25 expression
relative to donors homozygous for 176F (Fig. 7).
FcgRIIIa on NK cells is important in regulating NK cell
survival through receptor-mediated activation-induced cell
death (42–44). Both anti-CD16 mAb plus GAM cross-linker
and IgG aggregates decreased NK cell survival quite rapidly.
However, while comparable levels of cell survival were apparent after anti-CD16 mAb stimulation, there was a marked difference between 176F/F and 176V/V donors in the degree of
NK cell death after stimulation with IgG aggregates (Fig. 8).
Nuclear fragmentation and chromatin condensation, characteristic of apoptosis and assessed by transmission electron microscopy, was observed in NK cells stimulated via FcgRIIIa
(with cross-linked mAb or aggregated IgG) (results not shown).
In addition, quantitative PI staining of fixed and permeabilized
cells demonstrated a distinct population of apoptotic cells with
subdiploid DNA content in aggregated IgG stimulated but not
control cells (Fig. 9).
Characterization of the 176F/V polymorphism in donors with
disparate antibody-dependent cellular cytotoxicity (ADCC) activity. Because of the clearly defined differences in FcgRIIIainduced function in our homozygotes, we considered the possibility that the differences in quantitative ADCC by NK cells of
different donors, previously described by Vance (23), might reflect the 176F/V polymorphism. This possibility was reinforced
by the original observation that the difference in ligand binding among these donors was much greater than the difference
in mAb 3G8 binding. Accordingly, we made cDNA from
MNC preparations from six previously characterized individuals. Four low binding FcgRIIIa phenotype donors were homozygous for T 559 (176F), for T 230 (66L), and for C248 (72S)
while the two other donors, characterized phenotypically as
high binding FcgRIIIa, were G/T 559 heterozygous and homozygous for T 230 (66L) and for C 248 (72S) indicating that NK
cell ADCC is influenced by the 176F/V polymorphism (23).
These data demonstrate the functional importance of variation
of nt 559 in an independently phenotyped group of donors.
Association of the 176F allele with autoimmune disease.
We have shown previously that the low binding allele of FcgRIIa
(131H) is associated with SLE and nephritis in African-American patients (16). To determine if skewing of the normal
176F/V allelic system might also be associated with SLE, we
developed a genotyping assay based on allele-specific PCR.
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Figure 6. Aggregated hIgG and anti-CD16 mAb 3G8 induced rise in intracellular Ca21 levels in purified NK cells from donors homozygous for
FcgRIIIa-176V/V and FcgRIIIa-176F/F. Cells were isolated using a magnetic negative depletion strategy (Miltenyi NK Cell Isolation Kit) and
were . 90% CD56 and CD16 positive after isolation. NK cells were loaded with indo-1-AM and stimulated at 60 s with either 60 mg/ml aggregated hIgG (left) or were prelabeled with mAb 3G8 F(ab9)2 and then stimulated with F(ab9)2 GAM at 60 s (right). In all experiments, the rise in
[Ca21] induced with aggregated hIgG is much larger in the FcgRIIIa-176V/V donor (mean peak [Ca21] (nM) above baseline in 176V/V and
176F/F donors; 199621 and 67611, respectively, P , 0.01, n 5 3). Indistinguishable changes in [Ca21] in both donors were induced by crosslinked mAb 3G8 (mean peak [Ca21] (nM) above baseline in 176V/V and 176F/F donors; 555651 and 5266137, respectively, P . 0.05, n 5 3).
A representative experiment of three (with different donor pairs) is shown.

The fidelity of this assay was established using a genomic template from our initial group of FcgRIIIa sequenced normal donors (n 5 30) and confirmed by the sequencing of selected
SLE patients (n 5 38) and additional normal donors (n 5 11).
Using this assay, we genotyped a population of 200 ethnically
diverse patients with documented SLE and a cohort of 113
ethnically diverse normal individuals. There was a significant
skewing in the distribution of the three genotypes (3 3 2 contingency table, x2 5 9.87, P , 0.01; Table II) and in the allelic
frequency (2 3 2 contingency table, x2 5 6.13, P , 0.015; Table II) between the two groups. In the SLE patients, there was
an increase in homozygosity for 176F; 44% of the 200 SLE patients but only 23% in the 112 non-SLE control subjects were
176F homozygous. In contrast, only 4% of the 79 SLE patients
with nephritis were 176V/V homozygotes compared with 15%
of the 121 nonrenal SLE patients (15% in normal controls).
These results suggest that the presence of the FcgRIIIa 176F
allele is a significant risk factor for development of SLE, especially with nephritis.

Discussion
The recent observation of an FcgRIIIA sequence polymorphism on NK cells which influences ligand binding (24) raised
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the possibility that this sequence polymorphism might explain
previously described differences in NK FcgRIIIa and NK cell
function (23). To test this hypothesis we identified several of
these normal donors and characterized the nucleotide sequence of their FcgRIIIA. Contrary to our expectation, these
donors were monomorphic at nt 230 and nt 248 but polymorphic at nt 559. This polymorphism predicts an F to V substitution in position 176 of EC2 of FcgRIIIA, the domain which is
critical for ligand binding. Normal donors, homozygous for F
and for V at position 176 and homozygous for L at position 66
and for S at position 72 in all cases, were characterized for
ligand binding and for FcgRIIIa function. NK cells and monocytes from donors with 176V/V bound more IgG1 and IgG3
than the corresponding cells from 176F/F donors. FcgRIIIa176V/V elicited a larger flux in [Ca21]i, a greater degree of cell
activation, and a more pronounced program of activationinduced cell death than FcgRIIIa-176F/F. FcgRIIIa-176F/F individuals were overrepresented in a population of 200 SLE
patients while FcgRIIIa-176V/V individuals were underrepresented among patients with nephritis. These data, coupled with
other observations (14–20), suggest an important role for
FcgR polymorphisms in human disease.
The absence of the V allele in the phenotypic low binding
donors and its presence in the high binding donors strongly

Table II. Distribution of FcgRIIIa Alleles in SLE Patients and
Non-SLE Controls

Genotype*
No. of subjects (% of group)
176F/F
176F/V
176V/V
Allelic frequency‡
176F
176V

SLE patients

Non-SLE controls

n 5 200

n 5 113

87 (44%)
92 (46%)
21 (10%)

29 (26%)
69 (61%)
15 (13%)

0.67
0.33

0.56
0.44

A PCR-based genotyping assay (using genomic DNA) was developed
using allele specific primers (see Results). 200 ethnically diverse patients
with documented SLE (33) and 113 ethnically diverse normal volunteers
were genotyped for FcgRIIIa alleles [nt 559G (176V) and/or nt 559T
(176F)]. Allele and gene frequencies are shown. *SLE patients vs. normal controls; 3 3 2 contingency table, x2 5 9.87, P , 0.01; ‡ SLE patients
vs. normal controls; 2 3 2 contingency table, x2 5 6.13, P , 0.015.

suggest that this polymorphism explains the difference in NK
FcgRIIIa originally described by Vance and colleagues (23). In
that cohort, the tendency toward lower reactivity with mAb
3G8 among low binders is consistent with our data demonstrating the same subtle trend (Fig. 3 B and Table I). Most importantly, in the Vance study the ratio of IgG binding to mAb
3G8 reactivity clearly shows reduced ligand binding, even
when mAb 3G8 is used to define receptor number. Less clear,
however, is the relationship between the 176F/V polymorphism and the NK FcgRIIIa described in several patients with
recurrent infections (26). Both of those patients showed markedly reduced reactivity with mAb B73.1. Based on our data
that the B73.1 epitope is not influenced by position 176 and
other data indicating that 66R/R donors have markedly reduced levels of B73.1 reactivity (24), we anticipate that these
individuals with recurrent infections have some difference in
NK cell FcgRIIIa other than variation at position 176. Indeed,
the polymorphism at amino acid position 66 may contribute to
this difference (26). Quantitatively, however, the approximate
twofold increase in IgG1 binding reported for donors with 66R
or 66H compared with 66L parallels the magnitude of the difference in IgG binding we have seen with 176V compared with
176F. Although differences in ligand binding can influence susceptibility to infection (14, 15), this functional similarity between the polymorphisms at 66 and 176 and the prevalence of
the 176F/V polymorphism makes this mechanism an unlikely
basis for the rare patients described to date (26). However, the
similarity in ligand binding raises the interesting question of
whether the difference in ligand binding described for donors
varying in position 66 might be explained by allelic association
with position 176. To date, in more than 80 normal donors, we
have identified only two individuals who are heterozygous T/G
at nt 230 (66L/66R), one individual who is heterozygous T/A at
nt 230 (66L/66H), and one individual who is homozygous at nt
230 for the uncommon A allele (66H). Therefore, we have
been unable to test the hypothesis that 66R and 66H occur in
association with 176V and that 176V may determine the ligand
binding phenotype.

Figure 7. Aggregated hIgG and anti-CD16 mAb 3G8 induced upregulation of CD25 expression on purified NK cells from donors homozygous for FcgRIIIa-176V/V and FcgRIIIa-176F/F. Cells were isolated using a magnetic negative depletion strategy (Miltenyi NK Cell
Isolation Kit) and were . 90% CD56 and CD16 positive after isolation. CD25 expression was determined after cells were primed overnight with IL-2 (100 U/ml) and a with subsequent 2-h stimulation
with either 60 mg/ml aggregated hIgG (A), anti-CD16 mAb 3G8
(2.5 mg/ml) on GAM-coated plates (B), or buffer as control (C). Data
illustrated represent a single donor pair out of four different donor
pairs that were examined. The mean percent CD25 positive cells after
aggregated hIgG stimulation was 66.468.8 for 176V/V donors and
34.9619.4 for 176F/F donors (P , 0.03). Stimulation of NK cells from
176V/V and 176F/F donors with anti-CD16 mAb consistently produced a change in mean percent CD25 positive cells relative to control but there was no significant difference in the level of induction
between donors (P . 0.05).

There are several interesting implications of the FcgRIIIa
176F/V polymorphism. Recent data have suggested that FcgR
expressed on macrophages may play an important role in the
regulation of serum IgG levels. Initial observations in the
FcgRII knockout mouse demonstrated an impact on total IgG
levels, but since the entire FcgRII gene with its various splice
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Figure 8. Aggregated hIgG
and anti-CD16 mAb 3G8 induced cell death of purified
NK cells from donors homozygous for FcgRIIIa-176V/V
and FcgRIIIa-176F/F. Cells
were isolated using a magnetic
negative depletion strategy
(Miltenyi NK Cell Isolation
Kit) and were . 90% CD56
and CD16 positive after isolation. Cell viability was determined in the presence of trypan blue by cell counting by
two independent observers.
NK cells were stimulated for 24 h with IL-2 (100 U/ml) and then subsequently with buffer as control (open bars), anti-CD16 mAb 3G8
(2.5 mg/ml) on GAM-coated plates (striped bars), or 60 mg/ml aggregated hIgG (hatched bars). The mean number of cells remaining
(6SEM, n 5 4) for 176V/V donors after aggregated IgG stimulation
was significantly less than for 176F/F donors (P , 0.05); the two
groups were not different in control and anti-CD16 stimulation conditions.

isoforms was disrupted, the relative roles of FcgRIIb1 expressed on B cells as opposed to FcgRIIb2 expressed on macrophages could not be determined (50). Somewhat surprisingly, the naturally occurring disruption of the expression of
the FcgRIIb2 isoform expressed on macrophages of NOD
mice is strongly associated with upregulation of both IgG1 and
IgG2b serum levels despite relatively normal expression of the
B cell specific FcgRIIb1 (51). The possibility that macrophage
FcgR may be playing an important role in the regulation of
IgG levels is further underscored by the observation in humans that different alleles of FcgRIIa are associated with different serum levels of IgG2 (14). This observation is particularly important because in humans, FcgRIIa is expressed on
macrophages but not on B cells. Furthermore, this observation
emphasizes that alleles with different capacities to bind human
IgG2, not just presence or absence of receptor, are associated
with different levels of IgG. Thus, it seems reasonable to extrapolate to the prediction that the FcgRIIIa 176F/V alleles
may influence the level of IgG1 and IgG3. How they influence
specific responses to vaccination and net effective humoral immunity remains to be determined.
Of course the implications of the FcgRIIIa 176F/V poly-

morphism extend beyond the regulation of serum IgG levels.
Soluble FcgRIIIa is clearly present in the circulation (52–54).
In a number of systems, soluble receptor can influence the
level of B cell activation presumably through binding surface
immunoglobulin (55, 56). Since FcgRIIIa binds ligand with
higher affinity than FcgRIIIb which is unable to bind ligand in
monomeric form, FcgRIIIa may play a particularly important
role in mediating these effects. FcgRIIIa may also play a critical role in the first-dose cytokine-release syndrome seen with
some therapeutic monoclonal antibodies (57). Furthermore,
our earlier studies in a primate model of immune complex
handling demonstrated an essential role for FcgRIIIa (58, 59),
and more recent observations in mice with targeted disruption
of murine FcgRIII also support an important role in immune
complex–mediated triggering of inflammatory reactions (60).
Since each of these effects is dependent on binding of IgG, the
potential for FcgRIIIa 176F/V alleles to influence the biologic
potential of both receptor and ligand is clearly evident.
To directly test this potential in human biology in vivo, we
investigated the possibility that FcgRIIIa 176F/V alleles might
be abnormally represented in patients with SLE, a prototypic
immune complex disease. A role for abnormal FcgR function
in SLE has been described (61), and the skewing of FcgRIIa
alleles in SLE has supported the hypothesis that the FcgRIIa
allele with a low binding phenotype for human IgG2 would be
overrepresented in SLE (16, 17). In most immune complexes,
however, autoantibodies are not of the IgG2 isotype but rather
of the IgG1 and IgG3 isotypes. Thus, one might anticipate an
overrepresentation of 176F and an underrepresentation of
176V in immune complex disease. In our study of 200 ethnically diverse SLE patients, this skewing was very apparent
(Table II). Indeed, in patients with SLE and nephritis, the homozygous 176V was underrepresented by more than fourfold
compared with those without nephritis. We recognize that
these observations need confirmation in large independent
populations, that further stratification by clinical phenotype
and ethnicity may be insightful, and that studies of multiplex
families will be informative. We also recognize that this association may result from linkage to a different gene at another
locus. However, the biology of this polymorphism, its relevance to the pathophysiology of SLE, and the coincidence of
FcgRIIIa’s chromosomal location with a region of high interest in the microsatellite-based scanning of the genome in SLE
patients (62, 63), all make FcgRIIIa a likely gene for SLE disease risk.
Based on the biology of the FcgRIIIa-176F/V polymor-

Figure 9. Stimulation of purified IL-2
primed NK cells with hIgG aggregates induces the appearance of a subdiploid population of cells characteristic of apoptotic
cells. After overnight incubation with IL-2
(100 U/ml), cells were treated with buffer
(A) or IgG aggregates (B) for 1 h, 378C.
Cells were then fixed, permeabilized, and
stained for quantitative DNA content with
PI (see Methods). To allow discrimination
of cell doublets, PI width and PI area were
collected and cell fragments were excluded
through analysis of SSC (side light scatter)
and FSC (forward light scatter).
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phism, one can imagine that it could influence many antibodymediated responses involving IgG1 and IgG3. Since FcgRIIIa
is expressed on NK cells, mononuclear phagocytes, and renal
mesangial cells, host defense against viral, bacterial, and other
pathogens could be affected. Antibody-mediated immune surveillance could be altered as well as the interaction with immune complexes. Furthermore, the therapeutic response to intravenous gammaglobulin might vary in accordance with the
FcgRIIIa-176F/V polymorphism. Indeed, characterization of
Fcg receptor genotypes, in conjunction with other properties
of the humoral immune response such as antibody subclass
and complement status, may provide essential insights into
vaccine effectiveness and disease risk.
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